Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 5 of 5 clinical reviews.
A methodologically detailed look at the JUPITER trial's real limitations: enrollment biases, short follow-up, statistical caveats, industry funding concerns, and what subsequent investigators found when they looked more carefully at the data.
Read clinical reviewA deep methodological analysis of the JUPITER trial (rosuvastatin 20 mg vs placebo in adults with elevated hsCRP and normal LDL), examining randomization, blinding, endpoint adjudication, statistical design, and how each choice shaped the 44% MACE reduction finding.
Read clinical reviewA deep-dive into the cost-per-QALY analyses, payer-coverage implications, list-price vs net-price realities, and individual patient value calculations derived from the JUPITER trial of rosuvastatin 20 mg in primary prevention.
Read clinical reviewA detailed breakdown of the JUPITER trial's primary and secondary endpoints, effect sizes, confidence intervals, subgroup analyses, and time-course patterns for rosuvastatin 20 mg in primary CV prevention.
Read clinical reviewDetailed breakdown of JUPITER trial subgroup analyses for rosuvastatin 20 mg in primary prevention. Explores differential treatment effects by age, sex, BMI, race, Framingham risk, hsCRP, and baseline LDL.
Read clinical review